T-Cell Engagers vs. CAR-T: Which Approach Is Right?

T-cell engagers (TCEs) and CAR-T cell therapies both redirect a patient’s own T cells to kill tumor cells, but they achieve this through fundamentally different mechanisms, manufacturing pathways, and cost structures.

Choosing between the two approaches, or deciding whether to pursue both in parallel, depends on target biology, indication, patient population, and program timeline. The answers below address the core distinctions program leaders need to evaluate when selecting an immunotherapy modality.

What is the fundamental mechanistic difference between T-cell engagers and CAR-T?

T-cell engagers are bispecific or multispecific antibodies that physically bridge a T cell surface receptor, typically CD3, with a tumor antigen to form an immune synapse without engineering the T cell itself. This synapse bypasses normal T-cell receptor (TCR) specificity, redirecting any circulating T cell toward the tumor target the moment the molecule is administered. CAR-T, by contrast, requires genetically engineering a patient’s T cells to express a chimeric antigen receptor that permanently or transiently reprograms the cell to recognize and kill target-positive cells.

Because TCEs act as soluble off-the-shelf proteins while CAR-T cells are living engineered therapeutics, the two modalities diverge sharply in manufacturing complexity, onset of action, and persistence.

Nona Biosciences develops fully human heavy-chain-only antibody (HCAb) building blocks that support both approaches, since binders qualified through functional screening for CAR-T can, in principle, also serve as TCE components.

How do manufacturing costs and timelines compare between the two modalities?

Conventional autologous CAR-T manufacturing costs between $400,000 and $1 million per patient in real-world settings, while TCEs are manufactured as standard biologics with a defined, significantly lower-cost supply chain. CAR-T production requires leukapheresis to collect a patient’s T cells, followed by activation, viral transduction, and expansion over several days, a process that typically takes 3 to 4 weeks from collection to reinfusion.

TCEs skip this entire patient-specific manufacturing chain because they are produced as off-the-shelf antibody products, making them readily scalable across large patient populations. This cost and timeline gap is a major reason cell therapy has reached only around 20% of eligible patients in the US, while TCEs face no comparable manufacturing bottleneck.

Which modality delivers stronger efficacy in hematologic malignancies?

CAR-T therapies generally show better efficacy than currently approved TCEs in hematologic malignancies. All six FDA-approved CAR-T products target CD19 or BCMA, both effective targets for depleting malignant B cells, and their engineered persistence allows sustained tumor cell killing over time that a transient TCE dose may not match.

TCEs, however, still deliver meaningful clinical benefit with a markedly better safety and manufacturing profile, which is why the sector’s attention has returned to TCEs even as CAR-T maintains an efficacy edge. Programs targeting rapidly progressing hematologic disease should weigh CAR-T’s stronger efficacy against its 3-to-4-week manufacturing lag before defaulting to cell therapy.

Why are TCEs gaining renewed attention for autoimmune indications?

TCEs are considered especially amenable to autoimmune indications because of their low toxicity and straightforward, scalable supply chain. Autoimmune diseases typically involve large patient populations where existing management options already exist, making a therapy’s safety profile and manufacturing scalability decisive factors rather than efficacy alone. Because TCEs avoid the weeks-long, patient-specific manufacturing process required for CAR-T, they can be deployed at a scale that matches the size of typical autoimmune patient populations.

This combination of low toxicity, defined supply chain, and lower cost of goods has turned recent industry focus back toward TCEs for this indication category.

What structural engineering challenges limit CAR-T performance, and how are they being addressed?

CAR-T faces four core barriers in solid tumors: T-cell exhaustion from constant antigen stimulation, poor tumor infiltration in immunosuppressive microenvironments, antigen escape driven by tumor heterogeneity, and toxicities like cytokine release syndrome that require intensive monitoring. Many of these challenges trace back to the CAR’s antigen recognition module, meaning better construct design, not just better delivery, is often the more direct fix.

Traditional CAR designs rely on murine single-chain variable fragments (scFvs), which depend on VH-VL pairing and can misfold, aggregate, or trigger unwanted tonic signaling. Single-domain antibody formats avoid this pairing dependency entirely, offering more predictable CAR behavior and greater architectural flexibility, which is why the field has progressively shifted from scFv-based CARs toward single-domain binder formats.

Is a heavy-chain-only antibody (HCAb) the same as a camelid VHH nanobody?

No, these are related but distinct formats with different origins. A camelid VHH nanobody is a single-domain antibody naturally found in heavy-chain-only antibodies produced by camelids such as llamas and alpacas, weighing approximately 15 kDa. A fully human heavy-chain-only antibody (HCAb) is structurally analogous in that it also consists of a single variable domain without a paired light chain, but it is generated through Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies) using human VH gene segments rather than camelid biology.

Both formats share the practical advantages of small size, high stability, and freedom from VH-VL mispairing, but only the fully human HCAb format avoids the residual immunogenicity risk associated with a non-human sequence origin. In a Nona-led study comparing ROR1 HCAb-based CAR-T constructs against a conventional scFv CAR, the HCAb CAR consistently showed stronger tumor cell killing across increasing effector-to-target ratios, along with higher interferon-gamma secretion and increased granzyme B release.

How does binder choice affect immunogenicity risk in both TCEs and CAR-T?

Binder origin is a primary driver of immunogenicity in both modalities, and the field’s evolution has consistently moved toward fully human formats to reduce this risk. Early CAR-T constructs relied on murine scFvs, which can trigger anti-drug immune responses; the field then moved to humanized and fully human scFvs, though the VH-VL pairing and linker in these formats can still introduce structural and immunogenic liabilities. A cleaner approach uses fully human heavy-chain-only variable domains, which eliminate the linker entirely and reduce structural complexity.

This trend is documented clinically: the first camelid VHH-based CAR-T was approved in 2022, followed by the first fully human binding-domain CAR-T in 2023, confirming the industry’s clear prioritization of lower immunogenicity over time. In one clinical study using camelid-derived heavy-chain binders targeting BCMA, 7 of 15 patients relapsed, and 6 of those relapses coincided with dramatic drops in CAR-T persistence alongside detectable anti-CAR antibodies, illustrating how binder-driven immunogenicity can directly undermine durability.

When should a program choose a TCE over CAR-T, or pursue both in parallel?

Program teams should default to TCEs when speed to treatment, cost containment, and broad patient access are priorities, and reserve CAR-T for indications where its stronger persistence and depth of response justify the manufacturing burden. TCEs suit large-population indications, including many autoimmune diseases and hematologic malignancies where an off-the-shelf, scalable product is operationally necessary.

CAR-T remains the stronger choice when sustained, engineered persistence is required to achieve deep or durable remission, particularly in BCMA and CD19-directed hematologic programs. HCAbs from Harbour Mice® support both paths from a single discovery campaign, since binders qualified through functional CAR screening can also be engineered into TCE formats, reducing the need to run entirely separate discovery efforts for each modality.

How does Nona’s HBICE® platform address the structural limitations of conventional TCEs?

HBICE® (HCAb-Based Immune Cell Engager) is Nona’s platform for building T-cell engagers, TCR mimic antibodies & bispecific engineering from fully human heavy-chain-only binders rather than conventional antibody fragments. Because HCAb-derived single domains lack a light chain entirely, they eliminate the light-chain mismatching problem that constrains conventional multispecific antibody assembly, expanding the structural diversity and multiplicity of binders that can be incorporated into a single TCE molecule.

This structural flexibility allows CD3 binder affinity to be tuned specifically to balance cytotoxic potency against cytokine release, a critical tradeoff for maximizing the therapeutic window in TCE design. Nona Biosciences’ bispecific and multispecific engineering capability builds HBICE® constructs directly from this fully human single-domain foundation rather than retrofitting conventional IgG fragments into multispecific formats.

How does functional screening differ from standard binding-based selection for CAR-T and TCE candidates?

Functional screening evaluates candidate binders based on how they perform inside an actual CAR construct, not merely on binding affinity in isolation. Nona’s NonaCarFx™ (Nona’s CAR-based functional screening platform) integrates mammalian display with CAR activity readouts, allowing direct identification of HCAb-derived single domains that translate into strong CAR signaling and cytotoxic function. In a BCMA case study, a single-domain BCMA CAR already drove strong NFAT activation, while a dual-domain configuration produced an even stronger and more consistent signaling response in reporter assays.

This functional-first approach contrasts with conventional binding-based selection, which can advance binders that look strong in an ELISA or SPR assay but fail to translate into effective CAR signaling once expressed in a T cell.

Choosing between T-cell engagers and CAR-T does not need to mean starting two separate discovery campaigns. Programs evaluating both modalities in parallel can consult Nona Biosciences’ fully human antibody discovery team to qualify a single set of HCAb binders for functional performance across both CAR-T and TCE formats from the outset.

1. Kathryn M. Cappell and James N. Kochenderfer, Long-term outcomes following CAR T cell therapy: what we know so far, Nature Reviews Clinical Oncology, 2023. Link

2. Muyldermans S. et al., Nanobodies: Natural single-domain antibodies, Annual Review of Biochemistry, 2013. Link

3. June C.H. et al., CAR T cell immunotherapy for human cancer, Science, 2018. Link

4. Klein C. et al., The present and future of bispecific antibodies for cancer therapy, Nature Reviews Drug Discovery, 2024. Link

5. Ball K. et al., Achieving a therapeutic window for T-cell engagers: cytokine release and efficacy balance, mAbs, 2023. Link

6. Roybal K.T. and Lim W.A. Synthetic immunology: hacking immune cells to expand their therapeutic capabilities, Annual Review of Immunology, 2017. Link

7. Xu J., Chen L.J., Yang S.S., Sun Y., Wu W., Liu Y.F., et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma, 2019. Link